Lineage Cell Therapeutics settles Asterias merger lawsuit for $10.65M

Lineage Cell Therapeutics, Inc.

Settlement of $10.65M funded ~$7.12M by insurers and ~$3.53M by Lineage (cash or shares).
Lineage may issue unregistered common shares under Section 3(a)(10) for its portion.
Settlement subject to Delaware Chancery Court approval; denial would mean continued defense.
Defendants, including Lineage, deny all claims and no admission of liability.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Lineage Cell Therapeutics, Inc. entered into Stipulation and Agreement of Compromise and Settlement valued at $10.65 million (effective 2022-10-26).

Action: entry
Agreement: settlement
Value: $10.65 million
Effective: 2022-10-26

Exact text from the filing

On October 26, 2022, a Stipulation and Agreement of Compromise and Settlement (the “Settlement Agreement”) was entered into by the plaintiff, on behalf of himself and all others similarly situated, Lineage, and Messrs. Mulroy, Kingsley, LeBuhn and Mohanty.

View on SEC.gov

Browse all material agreements →

Lineage Cell Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-029887

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.